The BLA is supported by data from two phase 3, placebo-controlled trials, PROMISE 1 and PROMISE 2, which evaluated eptinezumab for episodic and chronic migraine prevention, respectively.

Fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic ... trials. Study results were maintained throughout the open-label extension ...

Migraine is a chronic ... eptinezumab (100 or 300 mg) or placebo by IV infusion for 24 weeks. Patients completing the 24-week double-blind period may be eligible to enter an open-label extension ...

placebo (p<0.0001) for both dose levels tested in the trial following ... If approved, eptinezumab has the potential to advance the treatment paradigm in chronic migraine prevention and be a ...

1 Dodick D, Smith T, Cady R, et al; Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials. Presented at the American Academy of ...

The 'PROMISE 2' study included 1,072 patients who were randomized to receive eptinezumab (300mg or 100mg), or placebo once every 12 weeks. Eptinezumab (Alder BioPharmaceuticals), an ...

Until 2007, evidence on the efficacy and safety of preventive medications used in the treatment of chronic migraine had been limited to case studies and open-label trials. The paucity of ...

More than half reported higher satisfaction with daily living and well-being after starting eptinezumab. DENVER — For those experiencing chronic migraine, the presence of self-reported ...